Discovery of a novel class of phosphodiesterase 10A inhibitors and identification of clinical candidate 2-[4-(1-methyl-4-pyridin-4-yl-1H-pyrazol-3-yl)-phenoxymethyl]-quinoline (PF-2545920) for the treatment of schizophrenia.

Autor: Verhoest PR; Neuroscience, Pfizer Global Research and Development, Eastern Point Road, Groton, CT 06340, USA. patrick.r.verhoest@pfizer.com, Chapin DS, Corman M, Fonseca K, Harms JF, Hou X, Marr ES, Menniti FS, Nelson F, O'Connor R, Pandit J, Proulx-Lafrance C, Schmidt AW, Schmidt CJ, Suiciak JA, Liras S

Publikováno v: Journal of medicinal chemistry [J Med Chem] 2009 Aug 27; Vol. 52 (16), pp. 5188-96.